Thank you for standing by, and welcome to the R1 RCM First Q uarter 2024 earnings conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. If you would like to ask a question during this time, simply press star followed by the number one on your telephone keypad. If you would like to withdraw your question, press the star one again. A reminder that this conference is also being recorded. I would now like to turn the conference over to Evan Smith, Senior Vice President, Investor Relations. Please go ahead. Thank you, Operator, and thank you everyone for joining us today. Certain statements made during this call may be considered forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In particular, any statements about our future growth plans and performance, including statements about our review of strategic alternatives, our strategic and cost savings initiatives, our liquidity position, our growth opportunities, our future financial performance, and the impacts of the Change Healthcare cyberattack and a customer bankruptcy on our business are forward-looking statements. These statements are often identified by the use of words such as anticipate, believe, estimate, intend, design, may, plan, project, would, and similar expressions or variations. Investors are cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements made on today's call involve risks and uncertainties. While we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so, except to the extent required by applicable law. Our actual results and outcomes may differ materially from those included in these forward-looking statements as a result of various factors, including, but not limited to, the impact that the review of strategic alternatives could have on our business or our stock price, the outcome and timing of the review of strategic alternatives, economic downturns and market conditions beyond our control, including high inflation, the quality of global financial markets, our ability to timely and successfully achieve the anticipated benefits and potential synergies of the acquisitions of Cloudmed and Acclara, our ability to retain existing customers or acquire new customers, the development of markets for our revenue cycle management offering, variability in the lead time of prospective customers, the later unsuccessful implementation of our technologies, including AI, competition within the market, and factors discussed under the heading Risk Factors in our most recent annual report on Form 10-K. Certain results that will be referenced on this call may be rounded to the nearest whole number. We will also be referencing Non-GAAP metrics on this call. For reconciliation of Non-GAAP metrics to the most closely comparable GAAP metrics, please refer to our press release. Now let me turn the call over to Lee. Lee? Thank you, Evan, and good morning, everyone. Our first quarter 2024 revenue results reflect positive trends in the underlying business as we continue to demonstrate our ability to drive value for our customers. The quarter includes Acclara contributions from the closing date in January, investments to onboard Providence, and continued investments in our multi-year technology transformation. We believe these technology investments will enhance our platform and drive innovation with new AI and advanced automation tools and solutions and development. We delivered approximately $604 million in revenue and $152 million in adjusted EBITDA for the first quarter. Before I provide more detail on our progress in the quarter, I want to reinforce my commitment and belief in R1's vision and strategy to deliver long-term sustainable growth and performance to our shareholders. Our vision is to be the automation platform of choice for the provider industry. We are distinctly positioned to solve a highly complex problem across the provider ecosystem with our combination of technology, global scale, and industry expertise to deliver revenue yields and cost reductions to the largest health systems and physician groups in the country. Today, we operate with the most scale of any technology and services provider in our space, with over 90 of the top 100 health systems as our customers. Our addressable market is large, at over $100 billion and growing, and we are well-positioned to win more than our share of this growing market over time. Technology is the foundation of our strategy, our value proposition to customers, and our place in the industry. We apply automation, AI, and large-scale analytics to the revenue cycle. We have visibility to large sets of structured and unstructured data across over 500 provider customers. This is where the scale of our platform matters most. For example, we apply machine learning models to automate clinical appeals and reduce payment timelines. We see clinical care episodes across all payers, all care settings, and all reimbursement model types, enabling us to apply models to validate certain charges and reimbursement levels for underpaid claims. These examples scratch the surface on the potential for the application of automation and AI when we are embedded in our customer's workflow. Global service capabilities are also core to our strategy. We are unique in that we operate our own facilities with our own people, our own processes, and IP. The combination of technology plus global scale is what allows us to deliver best-in-class unit economics and increased revenue yield to our customers. Now let me shift to execution on our priorities and our near-term outlook. We entered 2024 in a strong position to support long-term growth and improve performance. We have executed for our end-to-end clients, achieved solid bookings for our modular solutions, closed the Acclara acquisition, and started our 10-year strategic relationship with our largest new enterprise customer. We believe the continued strength of our commercial engine, delivering results to our existing clients, and ongoing investments in AI-driven technology and solutions will further support our growth throughout 2024 and over the coming years. Now let me turn to the Change Healthcare cyberattack, which had an impact across the healthcare industry. Given the central role R1 plays in the revenue cycle for our large, diversified customer base, it has impacted our near-term operating performance as well. Our operating team mobilized quickly and worked closely with those affected. In a matter of weeks, the team was able to successfully migrate 100% of affected customers to alternative claim clearinghouses. We also implemented technology and automation solutions to help mitigate both near-term and longer-term impacts surrounding claim submissions, processing, and ultimately, cash collections. Our unified data exchange, which is designed to integrate with every major EMR, payer, clearinghouse, bank, and other data sources, enabled R1 to support the implementation of alternative solutions and uphold data integrity and facilitate connections. We believe the challenges faced by providers as a result of the cyberattack have the potential to enhance demand for partners like R1 over time. Over the past several months, we have made progress against each of our focus areas for the year. As a reminder, these are: one, ensuring our growth strategy aligns with customer needs to meet them where they are on their revenue cycle journey. Two, continuing to deliver excellent operational results to our customers to maximize revenues and cash yield in these challenging times. And last, executing our technology roadmap to deliver innovation on behalf of our customers and drive measurable results above and beyond what they would otherwise be able to do on their own. First, our growth strategy. During the quarter, we saw traction with our flexible engagement model, enabling R1 to quickly align with new customers wherever they are in their revenue cycle journey. We demonstrated continued strength in our modular bookings and expanded our end-to-end pipeline, enhancing its breadth with additional opportunities for medium-sized health systems. We are also gaining traction in our sales activities for our functional model, adding new opportunities to our pipeline, which will support additional embedded growth opportunities over time. Second, operational execution. Our modular business remains central to our business model, driving diversification, delivering further cross-sell opportunities for both modular and end-to-end solutions, and providing the core advantage of data visibility across a wide spectrum of provider customers. We are succeeding in cross-selling and have grown to an average of more than three modular solutions per customer, with a long runway to drive additional growth. During the quarter, there was considerable interest in our Physician Advisory Solutions, DRG validation, Charge Capture, and underpayments, and we expect to see an increase in demand for denials and AR recovery going forward as a result of the Change Healthcare incident. Let me provide a couple of examples of our commercial success. We are already expanding the managed services or functional partnership we discussed in our year-end 2023 earnings call, having signed 2 new modular solution offerings in the recent quarter for both underpayments and retrospective Medicare bad debt. Another example is a long-standing multi-billion dollar NPR modular customer who uses most of our solutions, which further expanded the business for AR recovery solutions. Over the last 3 fiscal years, we have delivered over $60 million in value to this customer in AR recovery and denial solutions alone. We are also seeing success with regional hospitals. In 2023, we contracted with a $400 million NPR regional hospital to provide DRG and charge capture solutions, and were named vendor of choice for our CDI Total Performance Solutions. In the first quarter, we added a larger deal for inpatient clinical denials, and we are in discussion to expand our relationship across multiple solutions. Finally, we are also executing on our technology roadmap. With access to large-scale clinical, financial, and patient data powering our technology platform and advanced analytics, R1 remains at the forefront of helping leading providers transform their approach to financial performance and patient engagement. We have continued to apply technology to the revenue cycle to help our customers drive costs and revenue improvement. We have increased our technology investment in key areas of the revenue cycle to develop new GenAI solutions to further enhance or eliminate processes and leverage our global scale to address critical issues for our customers. In 2023, you heard me discuss several large language models that were launched. This included denials automation, next action prediction for AR management, and physician evaluation and management coding. As a result of these automations, we have identified additional value for our customers, improved the efficiency of our operators, and expanded our quality assurance capabilities, enabling continuous technological advancement and improvement. We anticipate launching several new solutions throughout 2024, which will put us at the forefront of innovating on behalf of our customers. An example of a particularly high impact use case delivered this quarter was our clinical appeal summarization large language model. This model is designed to reduce the time spent on denial appeal generation by 75% from an hour on average to 15 minutes. Instead of taking time to read through hundreds of pages of medical records, crafting the appropriate clinical argument, and drafting an appeal, this model is designed to complete this process and generate a draft letter. Our auditors then complete quality control to validate and edit the content as needed. We expect this use case will expand over time as we continue to review additional areas of our business that could utilize this automated drafting capability. In summary, we believe our vision to be the automation platform of choice for the provider industry is clear and achievable. Our strategy to meet providers where they are in their needs today matches a large and growing $100 billion addressable market, and we expect will help us continue to grow and further diversify our business. Lastly, our value proposition to the provider industry is strong, combining technology, global scale, and the best people in the industry. Thank you. With that, I'll turn the call over to Jennifer to discuss our quarterly financials and updated outlook. Thank you, Lee, and good morning, everyone. Our first quarter financial results demonstrate the progress we are making on some of our financial objectives, despite some disruption in the industry, as Lee just discussed. We delivered solid results in the first quarter, with revenue of $603.9 million and adjusted EBITDA of $152.2 million. These results demonstrate continued strength across the business. As Lee mentioned, we are pleased with our ability to respond quickly on behalf of our customers to mitigate disruption across the industry by the Change Healthcare cyber attack. Overall, approximately 50% of our customers' volumes flowed through the impacted vendor systems, with some impacted more significantly than others. We estimate that the disruption impacted the company's results by $9.5 million for both revenue and adjusted EBITDA in the first quarter. As Lee mentioned, we also had a large customer of our modular services filed for bankruptcy protection earlier this week. We did not record revenue for any unpaid work completed in the quarter, and we are fully reserved for all outstanding AR balances. This is the same customer that we reserved for in late 2023 as they were experiencing financial challenges. I will provide some details on these impacts in just a moment, but first, I want to give you an update on the financial results for the quarter. Total revenue grew by 11% year-over-year, which included growth in our base business, as well as the contribution from Acclara since we closed the acquisition on January 17th. This growth was partially offset by client attrition and facility divestitures we discussed last quarter, as well as the Change Healthcare outage and the bankruptcy of one of our modular customers that was filed earlier this week. Net operating fees of $381.5 million grew approximately 6% or $20.5 million year-over-year. This was mostly driven by the $19.2 million contribution from Acclara. Low single-digit growth in cash collections across our end-to-end customer base was offset by known attrition in the physician business and expected facility divestitures. The Change Healthcare cyber attack had no impact on our net operating fees in the quarter due to the lag of collections used in our base fee revenue calculations. Incentive fees were $15.6 million, which was below our expectations, primarily due to the Change Healthcare outage. This incident negatively impacted balance sheet metrics related to cash and AR that gets measured at the end of each quarter. We also expect the outage to impact our full year revenue, as some of these metrics will remain elevated for the next few quarters. Our modular and other revenue of $206.8 million grew by 28% or approximately $46 million year-over-year, driven by the addition of Acclara revenues, as well as the expansion of services to existing customers and new customer contracts. This was partially offset by the impact of both Change Healthcare and the customer bankruptcy. Turning to expenses for the quarter. Non-GAAP cost of services in Q1 was approximately $401 million, up roughly $39 million year-over-year. This includes approximately $46 million related to Acclara. Excluding Acclara, our underlying business expenses decreased due to the margin maturity on end-to-end customers, realization of synergies, and benefits from technology, offset by investments we continue to make in our tech platform. Non-GAAP SG&A expenses were $50.6 million, up approximately $9 million from the prior year. This increase is driven by a $6.7 million of expenses related to Acclara, as well as timing of expenses and corporate functions. Our adjusted EBITDA for the quarter was $152.2 million, which was in line with our internal expectations even after the impact from the incidents we faced this quarter. Continued cost discipline and the timing related to some Providence-related investments, which are now expected to occur over the next few quarters, reduced the impact of the lower incentive fees in the quarter. Lastly, we incurred $33.9 million in other expenses. This included roughly $16 million of transaction costs related to the Acclara acquisition. Now, let me provide a couple of comments on cash flow and the balance sheet. As I previously discussed, cash generation remains a focus for the company. Cash and cash equivalents at the end of March were $178 million, compared to $173.6 million at the end of December. For the quarter, we generated $46.7 million in cash from operations. Net debt at the end of the quarter was $2.1 billion, up approximately $651 million from the end of December. This increase reflects the additional debt in term loans and revolver borrowings for Acclara. Our liquidity also remains strong, with approximately $697 million at the end of March. This is both from cash on our balance sheet and borrowing capacity on our revolver. Now let me move to our 2024 outlook. As a result of the Change Healthcare cyber attack, we're updating our outlook to reflect the expected impact on revenue and adjusted EBITDA for the full year. We now expect revenue of $2.6 billion-$2.64 billion, growing 15%-17% year-over-year, GAAP operating income of $85 million-$105 million, and adjusted EBITDA of $625 million-$650 million. These expectations reflect the full year 2024 impact of the Change Healthcare cyber attack and the contribution of Acclara, as well as the new contract with Providence. As a reminder, R1's revenue is tied to cash collections, which was impacted by the Change Healthcare cyber attack. As Lee indicated, while we've successfully transitioned our clients to alternative clearing houses, the disruption will impact the timing of net operating fee revenue as we move through the year. Specifically, we expect a large shift in timing between our Q3 and Q4 net operating fee revenues based on the backlog of claims and cash during March, April, and May. We expect most of the cash from these claims will be settled by August, which is the last month of collections that will drive our Q4 net operating fees. At this point, given our utilization outlook is not changed, we believe the impact to net operating fee revenues is just a shift in timing between the quarters. As we experienced in the first quarter, we do expect a reduction in incentive fees in the full year, as we will not be able to earn back lost revenues from missed balance sheet metrics for AR and cash until the recovery is complete. In total, for the full year, we expect the impact from the outage will be approximately $20 million in revenue and approximately $25 million in adjusted EBITDA. This is driven by the revenue impact I just mentioned and additional costs of approximately $2 million per quarter for the rest of 2024, primarily related to the backlog of claims and manual efforts that will be required to support our clients. Our outlook also assumes the following: low single-digit year-over-year growth for our net operating fees from existing customers. Customer attrition and facility divestitures are consistent with our original outlook. We also remain confident in the onboarding of Providence and expect that contract to be materially in line with our previous guidance. With respect to Acclara, we are revising our outlook to reflect that we plan to harmonize certain lines of business and customer contracts. We anticipate this will support our adjusted EBITDA outlook as we move into 2025. As a result, we now expect Acclara to contribute approximately $275 million-$280 million of revenue in 2024. $25 million of adjusted EBITDA is consistent with our original guidance. We expect modular and other revenue, excluding the impact of Acclara, to grow low double digits. Regarding the client bankruptcy, we have not removed the revenue from our outlook, given R1 service providers were designated as critical vendors in the filing early this week. We estimate $45 million in modular revenue for this customer in our full-year outlook. Based on the above factors, we now expect Adjusted EBITDA to be in the range of $625 million-$650 million. This outlook also assumes capital expenditures of approximately 5% of revenue, other expenses of approximately $105 million-$120 million, including Acclara transaction costs and integrated related expenses. Interest expense in the range of $175 million-$180 million, including the increased debt to fund Acclara, and depreciation and amortization expense of $330 million-$350 million. In closing, we had a good quarter, and we are pleased with the great work from our 30,000 global colleagues. We came together as a team this quarter, and I'm incredibly proud and grateful to work with some of the best healthcare experts in the industry to deliver for our customers. With that, I'll turn it back over to the operator. Thank you. As mentioned, we are now open for questions. To ask a question, please press star one on your telephone keypad to raise your hand and join the queue. If you would like to withdraw your question, simply press star one again. In the interest of time and to ensure we cover as many participants as possible, we do request a limit of one question per person. Your first question comes from the line of Charles Rhyee from TD Cowen. Please go ahead. Yeah, thanks for taking the questions. I wanted to just dive into this impact on the Change Healthcare outage. You know, with the guidance, is it fair to think that the full impact of Change Healthcare is really just captured completely into 2024? Or is there a chance that some of that impact could fall into next year? And then, you know, Jennifer, I think you said obviously some of the incentive fees that you can't capture, which are sort of balance sheet items at the end of the period. But did I hear correctly that some of that could be recaptured at a later date on the balance sheet items? And then, sorry, lastly, any kind of sense for if we have this shift of Q3, Q4, could you give us a sense what, how Q2 should look, in terms of, revs and adjusted EBITDA? Thanks. Hi, Charles, this is Lee. Why don't I start with just, you know, big picture, how we've addressed this challenge, and then I'll hand it over to Jennifer to answer the specific question on, on timing. So let me, let me just talk about long-term impact, what the team did to address the situation, and just maybe a few lessons learned, because I know this would be a common question if I don't hit this up front, and then we'll talk about the specifics. Long term, strategically, no impact. The core business is strong. If anything, this emphasized the need for technology and automation with all of our host systems. You know, we'll, we'll address the near-term impact, but clearly, there's a near-term impact for our customers and for our business. But long term, you know, we feel very solid about our business and what we've done through this challenge. The second thing is, the team mobilized very quickly on behalf of our customers, assessed three main alternatives, technology vendors that you would know, alternative clearing houses, and within a matter of weeks, got them up and running on those clearing houses. Now, we do expect some residual impact on KPIs with regard to denials because we have built-in automations with many of our vendors, many of our host systems. So you know, we do expect some KPI impact back half of this year, but we feel very good about the work we did on behalf of our customers to get them up and running over the last couple of weeks. You know, in terms of lessons learned, clearly, the number one by far is the importance of information security relative to what's happening in our industry. This is an attack on one company, but could happen to any company in our industry. The second lesson learned is around vendor dependency. We've, you know, clearly looked across our customer base, across our own internal systems to identify any other dependencies. This happens to be a pretty unique situation with Change. And third, the importance of technology scale. So us being able to invest on behalf of our customers, fix the issues, get ahead of it, and resolve the issues. Jennifer, do you want to answer the specifics on some of the timing questions? Sure. Let me just give you a little bit of clarity in the way we're thinking about Change Healthcare in total, and it's really in three areas. The first is related to revenue on KPIs, and Charles, you asked about some of the metrics. There are three areas of KPIs, three metrics that we're monitoring, and we think that there will be impacts on. It's cash, AR, and then, as Lee just mentioned, on denials. Cash and AR, the balance sheet metrics, and there was obviously a large impact in Q1, and we think that the, the AR will remain elevated for the next couple of quarters, so there will be some impact on KPIs related to those. Cash, we will have the opportunity to recoup some of the Q1 impact because cash will come back in Q2 and Q3, which will help a little bit. And then KPIs will be impacted in Q4, we believe, by the denials that Lee just mentioned. So really, net-net, the big impacts on KPIs will be first quarter and fourth quarter, with kind of some noise in between metrics in Q2 and Q3. The second one is timing, and think about it in two different buckets. On modular, there was an impact in Q1, and we expect a little bit of impact in Q2, and that's really just timing. So when the cash and the backlog comes through, we expect that that will come back in the second half of the year. The larger impact is on our base fees, and remember, we have a four-month lag. So the way to think about that is cash collections in March, April, and May, which will be the biggest timeframe of an impact to cash for our customers, that is our Q3 base fee revenue. And then June, July, and August is Q4. So we expect a big fluctuation between our Q3 and our Q4 base fees, but we're considering that timing between quarters. Large fluctuation, but really no net impact for the year. And then the third bucket of Change impact is costs. And as you heard in the prepared remarks, about $2 million of costs - incremental costs expected in the balance of the year per quarter, and that's really driven by incremental labor, either in the form of incremental people and/or contractors and overtime associated with manual efforts. So as Lee just mentioned, we have a lot of automations and rules built into some of that front-end Change Healthcare software, and as we've transitioned to other vendors, we've got to rebuild those automations. We've been building those rules in over years and years, so it will take some time to get back up to the efficiency level that we expect. In the short term, we've got a backlog of claims that we've got to work through. Got it. Appreciate the color. Thank you. Before we continue on to the next question, a reminder to please limit to one question per person. Your next question comes from the line of Craig Hettenbach from Morgan Stanley. Please go ahead. Great. Thank you. Lee, question on Providence, really around visibility into the ramp of that contract and just, you know, the investments you're making the first half of this year, how you feel it's going so far, and then again, visibility into second half and the ramp into 2025? Thanks, Craig. You know, I'll start on this, Jennifer. If you have any other color, please feel free to add. You know, stepping back, this is obviously an important customer, a flagship win for our business. We're very proud of having been selected as their partner, both on the Acclara and on the Providence side. All is positive, Craig. There's a very supportive, a very strong executive team on their side, very aligned set of goals and incentives. And on regarding execution of onboarding, we're following a playbook that has worked for other large acute physician and physician customers. We have a very experienced R1 onboarding team. There's, you know, lots of moving parts, bringing on that many people, getting onto their technologies, transitioning to our teams, but all is on track. We feel very good about timing of onboarding and integration. Jennifer, anything to add? Just as we mentioned in our prepared remarks, from a guidance perspective, we're materially in line with the guidance that we gave for the Providence contract, and we're confident in our ability to achieve those results. Your next question comes from the line of Elizabeth Anderson from Evercore. Please go ahead. Hi, guys. Thanks so much for the question. I appreciate the sensitivity around this. I was wondering if there's anything that you guys can comment on publicly about the update in the May 6 waiver. And if not, I was wondering if you could comment a little bit more on sort of the increased harmonization with Acclara. I was interested in understanding, like, what more that is, does that... And then how does that sort of set you up better for 2025, as you mentioned? Yeah. Thanks, Elizabeth. Look, no update other than what's publicly available on your first question. You know, we're very focused on operating on behalf of our customers and not letting this distract our team. With regard to Acclara, look, I'm very positive on what we've seen a few months in. A very solid set of customers, including several reasonably sized academic medical centers, and these are sophisticated buyers. So we've gotten deep, had a good set of meetings with those customers, and they are very pleased with the work that Acclara has done on their behalf over the last several years. The second thing I'd point out is that team has very deep revenue cycle expertise. I've gotten to know the leaders on that team, and there's a healthy amount of respect between the R1 and Acclara teams on level of expertise, ability to deploy technology, customer focus, and just relations, relationships they have with their customers. We are taking a very similar approach to integration that we took with Cloudmed, a very structured approach, commercially, operationally, with regard to people and all the kind of back-end processes. All of that is on track, so we feel very good about the process we followed with integration and, you know, no, no, no concerns. I'm just very positive on the business so far, in terms of how complementary they are to what we've already deployed with customers. The only thing I would add on the harmonization, Elizabeth, is two things. One, at the time we announced the transaction with Acclara, as you may recall, the margins are obviously below what our margins are in the business. And so as we're starting to think about integration and looking at those businesses, we're taking a hard look at, you know, businesses and certain solutions that aren't profitable and taking the opportunity to think about harmonization, and that will really set us up well as we move into 2025. But it will have a revenue impact, but really no impact on EBITDA, as there were areas or contracts where we didn't have any profitability, in some cases, negative margins. So that's one area. The second is particularly around some of the opportunities that Acclara had with Providence as we're sorting out the end-to-end contract, and where the revenue will end up. There will be some revenue impacts on Acclara on the top line, but they were already contemplated in the base fee for Providence. And so there's no margin impact because it's already part of the baseline spend with Providence, that they're spending either with other vendors or Acclara had contemplated taking on some of that business. So just sorting out how the revenue aligns across the different businesses, but really no impact to margin. Your next question comes from the line of Jailendra Singh from Truist Securities. Please go ahead. Thank you, and good morning, and thanks for taking my question. First, a quick clarification on Charles's question. So you're saying that there is no change to your core 2024 EBITDA, what you kind of assumed 2.5 months back? Basically, we're trying to understand, like, looks like all the items you're calling out are kind of one-time in nature or shift of dollars within, like intra-year. So basically, how we think about the growth from 2024 to 2025, there's no change compared to 2.5 months back. I want to confirm that. My main question is like, with respect to Change Healthcare disruption, has it impacted your pipeline, RFP flow, or conversations in general? Also, like all these developments around strategic options, have you seen that impacting your any ongoing contract rollouts or any client conversations? Jailendra, I'll start on the change impact, and then, Lee, if you want to take the pipeline piece and the impact on that. As far as the KPIs, we do expect that we will have some of the KPI impact bleed into 2025, into the first half of 2025, and that's really driven by denials, as we expect that denials will be elevated for a period of time as we continue to build in the automations on the front end of where we've, you know, built rules over a period of time that have to be rebuilt, if you will, in the new providers' clearinghouse process. So we do expect that there will be an impact to KPIs in the first half of 2025. With that said, if you look at the change to the guidance, it really is net net the change impact, both cost and then the net KPI impact. There's no fundamental issue in the business, on the core business, outside of that net impact. Just let me get to the second part of that. No long-term impact on the pipeline. We did see a 3- or 4-week delay, but the team is very much on track, both in the quarter and for full year on bookings, and I'm speaking specifically to modular bookings, Jailendra. If anything, there's an opportunity here, as any customer who deals with the outage will have an increase in denials, we think, back half of the year. So we are seeing an increase in the pipeline around AR and denials. Apologies for that interruption. Your next question comes from the line of Sean Dodge from RBC Capital Markets. Please go ahead. Yeah, thanks. Just, Jennifer, just staying on the change outage for a moment. I'm just trying to understand the cadence of the impact, the incentive fees, for this year. So you said $25 million of total impact to the year, $10 million in Q1, and then $2 million of extra costs each quarter for the rest of the year. So I think that means there should be about another $9 million impact to incentive fees. Is that right? And then cadence-wise, it sounds like there might be a little bit of a step-up in Q2 incentive fees relative to Q1, kind of flattish in Q3, and then a step down in Q4. Am I kind of aggregating all that right? Yeah, that's right. There will be the other large negative impact expected on incentive fees is in Q4, and there's just a little bit of noise, but a step up in incentive fees, but still a little bit of noise in Q2 and Q3, but then another impact in Q4 that's really driven by that denials. So yes, that's correct. Your next question comes from the line of George Hill from Deutsche Bank. Please go ahead. Yeah, good morning, guys. I kind of have a follow-up on Jailendra's line of questioning, which is on the market macro backdrop. And with the onboarding of Providence and the acquisition of Acclara, has this kind of increased or decreased the size of the sales funnel looking forward? And how are you guys feeling about capacity as it relates to whether or not this is attracting more business interest or what, like, are potential clients seeing this as like, as you guys is the safe place to go now, or are people worried that you guys have a lot on your plate? Just kind of be interested in the sales pipeline and the sales funnel. Thanks. George, short answer is no impact. You know, short term in nature on the pipeline, modular pipeline, we're still seeing plenty of opportunities and increases in some areas like AR and denials, and same on the end-to-end pipeline. We're feeling very good about what's happening there. Seeing many or several medium, small and medium-sized systems. We're very active in discussions across the board there, so no changes across. If anything, this just heightens the awareness of needing good partners that can deploy technology and services. And I'd also add, George, on your Providence question, look, these are separate teams, very focused teams. No impact to onboarding Providence or integrating Acclara. Your next question comes from the line of Jack Wallace from Guggenheim Securities. Please go ahead. Hey, thanks for taking my questions. Jennifer, I just want to make sure that I've got the net impact of first quarter EBITDA correct, and then give me an opportunity to tell us just how much, you know, outperformance there looked like under the surface. So if I recall correctly, first quarter EBITDA was expected to be down about $20 million quarter-over-quarter related to some of the transactions we discussed, but you're only down about $16 million. That also included, what, $9 million or $10 million of Change. So are we right to say that under the surface there's about $13 million or $14 million of EBITDA beaten the quarter? We did have a good quarter with our core business. We also alluded to it in the prepared remarks. Some of our first quarter favorability was driven by timing of the investments on the Providence onboarding. So there are some one-time costs that we incur on onboarding related to things like technology licenses and, you know, some other technology costs that we expect will come in Q2 and Q3. So some of that is timing, but we did have a great quarter. Your next question comes from the line of Michael Cherny from Leerink Partners. Please go ahead. Good morning. Thanks for taking the question. And I apologize if I missed this, but did you give any update on Sutter, either in the current ongoing onboarding process or how you think about the changes in management there, what it means for phase two? Thanks, Michael. I'll take that. You know, I'd say, look, this is a very important customer, another West Coast customer, that we won several years ago, broadly performing well. Like any customer, there's always opportunities for improvement, as we manage an important part of their business. I would think of what we- you have called phase two as, like with many of our end-to-end customers, an opportunity going forward. Your next question comes from the line of Sarah James from Cantor Fitzgerald. Your line is open. Sarah, your line is open. Yeah, sorry about that. Is there an opportunity to cover some of the switching costs with related to change to other vendors through business interruption insurance? And are those changes of vendors permanent? And then if you could give us any color on the seasonality of impact of change to net operating revenues. Thanks. So, Sarah, the first part of your question, I don't want to get into any specifics, but clearly we, like many other companies, are pursuing different options regarding insurance. The second part of your question is an important one. You know, we're going forward will you know never be single-threaded through any one technology on a large use case, whether it's you know clearinghouse or otherwise. I would think of this as us diversifying our base of options regarding this area. Some of those will be more permanent than others, but for the most part, any of our customers will have multiple options and deploy not just one for this use case. And then on your last question related to the timing of base fees, we really think it will be a large impact, fluctuation and shift in timing between Q3 and Q4 base fee revenue, probably in the range of, you know, somewhere between, you know, $25 million-$30 million. Your next question comes from the line of Daniel Grosslight from Citi. Please go ahead. Hey, guys. Thanks for taking the question. More of a macro question on my end, and really about the managed care environment, particularly given some difficulties in Medicare Advantage. I'm wondering if, you know, if some of those headwinds that Medicare Advantage faces in 2025 and possibly beyond, if that's going to cause, do you think, an increase in utilization management tools, and how may that impact collections on your end and incentive fees on your end? And then, I guess, longer term, how may that drive demand for some of your more modular solutions? Yeah. So it's a great question. I'd say pretty balanced across the board on the macro outlook. So I love the last part of your question. It does drive demand as some of our customers deal with, you know, the nature of payment timelines with MA, and some of the technologies they'll deploy on the reimbursement side. Some of our customers do have, you know, reasonably reasonable sizes of their population on MA. And look, if anything, this emphasizes the importance of having a technology partner that can be as proactive on driving revenue yield and reducing costs. So pretty balanced across the board. No major changes over the last, you know, year plus, Jennifer and I have seen, but we're definitely watching that trend going forward. Anything to add, Jennifer? Good. Your next question comes from the line of Jeff Garro from Stephens. Your line is open. Yeah, good morning. Thanks for taking the question. Want to ask more on the demand environment, and, you know, certainly recognize that the business model is evolving and you guys don't want to tie yourself to end-to-end NPR targets, and also appreciate all the discrete examples of booking success. But wanted to ask if there's any way you could quantify your booking success or the progression of opportunities through the pipeline, or just otherwise support your confidence in the medium-term revenue growth outlook. Thanks. Jeff, you know, I'll just touch at a high level on the demand environment. So I'll go a bit deeper on what we've said, meeting providers where they are on their revenue cycle journey. We believe we have the most comprehensive set of capabilities of solutions, whether you want a fully managed deal, or on the other spectrum, have us help you drive revenue that you would not otherwise be able to find based on miscoding errors, you know, lack of availability of resources to deal with denials, or analyze claims that may have been underpaid. And in the middle is what we're calling, you know, our managed services or functional partnerships. And we are seeing plenty of situations where it is better for us and better for the potential customer to go down the path of using our people, our technology, our IP offshore to accomplish a task while having the customer manage, still manage the revenue cycle. So we see good demand across the board. On the end-to-end side, as I said, a strong pipeline of medium-size systems that would look to do a fully managed deal. And on the other spectrum, on the modular side, still see very strong demand. Where we're seeing it the most is still on the underpayments optimization area. We see plenty on the denials and AR side. We're seeing demand for Physician Advisory Solutions and continued demand on the coding accuracy side. So we see strong demand across the industry in a time where we believe providers need us the most. Your next question comes from the line of Richard Close from Canaccord Genuity. Please go ahead. Thanks for the questions, and, good job helping out all your clients in a hard time here. Jennifer, you mentioned the bankruptcy in your comments on the modular revenue in the quarter. I was wondering if you could provide a little bit more details there, and appreciate the $45 million for the full year that you referenced. But I, I'm curious how you're thinking about the bankruptcy and the impact on your business going forward longer term. Richard, if you don't mind, I'm gonna start, just kind of give a little context, then hand it over to Jennifer. This is an important customer for both Acclara and Cloudmed. Longstanding customer on both sides, I'm personally familiar with, and our Acclara teams are very familiar with. Multiple solutions sold on both sides. This is a customer that has highly valued the combination of technology, global scale, and the solutions we have. They have filed for bankruptcy, as you know. We are committed to helping them through this, as we have helped others in similar situations, so we feel very good about the, the work we will do for them going forward. Jennifer? Sure. So I mentioned in the remarks about $45 million is what the annual revenue is across both pieces of the business, Acclara Solutions and Cloudmed Solutions, for this customer. With that said, in the first quarter, we did not recognize any revenue that was not collected, so we received cash payments for all the revenue that we recognized in the first quarter. Any of the outstanding AR that we had on the books is fully reserved at the point that they filed for bankruptcy this week. So there's no exposure from a balance sheet perspective based on the outstanding receivables. This is the same customer, as you may recall from prior earnings calls, where we took a reserve in the latter part of 2023 based on financial challenges we knew this customer had, and so we had taken a reserve to account for that. So this is the same customer. As far as looking forward, we have not removed the revenue from our guidance for the year. They, as I mentioned, they just filed earlier this week, but in the initial filings, they have designated revenue cycle vendors as being critical to the operations of the business. So we're working through the bankruptcy process, but we have not removed the revenue from our forecast, as we do believe we'll still be doing work for them going forward. Your next question comes from the line of Allen Lutz from Bank of America. Please go ahead. Good morning, and thanks for taking the questions. Lee, you talked a little bit about some of the benefits you're seeing in modular solutions from Change Healthcare. I think you highlighted AR and denial recovery. Is there any way to quantify how material those are as modular solutions, or, what percent of your customers have adopted those to date? Thanks. Allen, the way I think about this, at the highest level is, we have more than 90 of the top 100 that we've previously said have at least one solution sold. A big part of the former Cloudmed, now modular strategy, has been to cross-sell into that customer base. So one metric is the number of solutions sold, and I mentioned in my previous remarks, we're increasing the number of solutions sold into that base. And that is historically, and continues to be, a big part of our growth strategy. Really think about that as, you know, 75% or more of our growth is coming from current customers, not just the top 100, but also when you go past the top 100. The next part of our strategy is attacking new markets we haven't kind of gone after before, and that is for us, going down market with bundled solutions. We're also seeing success there. The third part that we think about is cross-selling some of the, what we would know as historic, kind of, R1 modular solutions, like physician advisory, our coding solutions we call CBO, into the base. So we very much track the rate of penetration of those new solutions into the base, and we're seeing really good success there with our commercial teams that already have relationships with every head of revenue cycle at these top 100, by NPR. You know, without giving you numbers, we have a bookings target we articulate internally that translates to revenue over time and delivers the double-digit growth rates we've conveyed to you, and we're very much on track in the quarter and expect to be on track in the year. The only thing I would add is the denials is at one of our larger solution lines within our modular business. But with that, as Lee mentioned, there's still a lot of opportunity for further penetration across our customer base. A reminder, if you would like to join the queue and ask a question, please press star one on your keypad now to raise your hand, and we'll pause for a moment for any final questions. There are no final questions at this time. I would like to turn the call back over to Lee for closing remarks. Thanks, Paulie. A couple of things I'd say just to close us out. First and foremost, we remain focused on delivering operationally and innovating for our customers. That's by far our top priority. Second, is a point that I've emphasized a few times, is that market demand for our solutions is very strong across the board. And third and last, we're very excited about the opportunity to transform the industry through technology and what we believe are the best people in the industry. Thank you for your time today, everyone. This concludes today's conference call. Enjoy the rest of your day. You may now disconnect.